Tarlatamab for IDH-mutant brain tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a new drug called tarlatamab is safe and effective for people with certain types of brain tumors that have an IDH mutation. You may be eligible if you have had up to 2 prior treatments after the tumor returned, and you are either having surgery to remove the tumor or the tumor cannot be removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a brain tumor called a diffuse astrocytic or oligodendroglial tumor with an IDH mutation.
- You are 18 years or older and weigh more than 40 kg (about 88 lbs).
- You have had no more than 2 treatments since the tumor returned.
- You are well enough to carry out daily activities (ECOG score 0 or 1) and have a life expectancy of at least 12 weeks.
- You must agree to use two effective methods of birth control if you are able to become pregnant.
- You are willing to provide tumor samples (if having surgery) and stay near the hospital for 48–72 hours after the first two doses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
This study tests a drug called tarlatamab given before and after brain surgery for people with a recurrent high-grade glioma. The goal is to see if the drug is safe and helps the body fight the tumor.
This trial tests a new combination of two drugs (tarlatamab and temozolomide) for people with certain types of aggressive brain or central nervous system tumors that have come back or not responded to standard treatment. The hope is that this combination may work better against tumors that have a specific marker called DLL3.
This trial tests a new drug called tarlatamab for people with advanced small cell or neuroendocrine cancers that started outside the lung (like in the stomach, bladder, or head and neck) and have grown after initial chemotherapy. It aims to see if this treatment can shrink or control the cancer.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
This trial tests a new drug called Tarlatamab for people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) of the digestive system that has stopped responding to prior chemotherapy. The drug targets a protein called DLL3 found on some tumors, and researchers hope it can shrink or slow tumor growth.
Hear when a new Astrocytic Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.